Trials to regrow knee cartilage

I reported previously (Nov 2016) that Israel’s Regentis was to begin Phase III trials on its GelrinC, treatment for cartilage damage in the knee. The study has now been extended to 11 US sites involving 120 patients. The GelrinC implant encourages stem cells to re-grow cartilage.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *